BillionToOne, Inc. (BLLN) vs NeoGenomics, Inc. (NEO)
- BillionToOne, Inc. BLLN 98.06 −4.55%
- NeoGenomics, Inc. NEO 16.65 −3.48%
BillionToOne, Inc. and NeoGenomics, Inc. are both Diagnostics & Research companies. BillionToOne, Inc. is the larger, with a market value of $4.9B against $2.2B — 2.2× the size. NeoGenomics, Inc. has negative trailing earnings, so its P/E is not meaningful; BillionToOne, Inc. trades at 95.0×. BillionToOne, Inc. has the higher net margin (8.35% vs −6.77%) and the higher return on invested capital (34.1% vs −4.20%). Across the 16 metrics below, BillionToOne, Inc. leads on 13 and NeoGenomics, Inc. on 3.
Valuation
Profitability
| Metric | BLLN | NEO | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 71.27% | 43.92% | 50.89% |
| Operating margin | 10.90% | (8.93%) | (8.57%) |
| Net margin | 8.35% | (6.77%) | (6.37%) |
| Free cash flow margin | 8.35% | (0.69%) | 0.00% |
| Return on equity | 23.27% | (6.33%) | (2.92%) |
| Return on assets | 9.09% | (3.78%) | (6.71%) |
| Return on invested capital | 34.10% | (4.20%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack